204 results match your criteria: "Duke University Medical Center and Duke Clinical Research Institute[Affiliation]"
Diabetes, Subclinical Myocardial Injury or Stress and Risk of Heart Failure Subtypes: The Jackson Heart Study.
Diabetes Care
January 2025
Division of Endocrinology, Diabetes & Metabolism, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD.
Objective: To assess the extent to which the concomitant presence of subclinical myocardial injury or stress and diabetes affects the risk of heart failure (HF) subtypes.
Research Design And Methods: The Jackson Heart Study included Black adults, categorized based on diabetes status, high-sensitivity cardiac troponin I (hs-cTnI), and brain natriuretic peptide (BNP) levels. Subclinical myocardial injury was defined as hs-cTnI ≥4 ng/L in women and ≥6 ng/L in men, and subclinical myocardial stress as BNP ≥35 pg/mL.
A Time for Reflection and Renewal.
J Card Fail
December 2024
Duke University Medical Center and Duke Clinical Research Institute, Durham, NC, USA.
Spotlight on Devices in Heart Failure.
J Card Fail
November 2024
Mount Sinai Fuster Heart Hospital and Department of Population Health Science and Policy, Mount Sinai, New York, NY, USA.
Impact as a Metric: Always in Motion.
J Card Fail
September 2024
Duke University Medical Center and Duke Clinical Research Institute, Durham, NC, USA.
Metabolic dysfunction and incidence of heart failure subtypes among Black individuals: The Jackson Heart Study.
Eur J Heart Fail
September 2024
Department of Medicine, Division of Endocrinology, Diabetes & Metabolism, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Article Synopsis
- The study investigated how the severity of metabolic syndrome (MetS) impacts the risk of developing heart failure (HF) among Black individuals, focusing on different subtypes of HF, specifically HF with preserved ejection fraction (HFpEF) and reduced ejection fraction (HFrEF).
- In a sample of 4,069 participants, those with higher MetS severity showed a significantly increased risk of HF, with a twofold greater risk overall and an even higher risk associated with HFpEF.
- The findings suggest that maintaining good metabolic health is crucial for reducing the incidence of heart failure, particularly among Black individuals.
JCF Purple for Patients.
J Card Fail
August 2024
Zena and Michael A. Wiener Cardiovascular Institute and Department of Population Health Science and Policy, Mount Sinai, New York, NY, USA. Electronic address:
Enhancing patient acceptance of ICD implantation through structured shared decision making: conversation is key.
J Interv Card Electrophysiol
December 2024
Division of Cardiovascular Medicine, Department of Medicine, University of California, San Diego, CA, USA.
Background: Implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-D) are lifesaving treatments for patients at risk for sudden cardiac death. Effective physician-patient communication during the shared decision-making process is essential. Electrophysiologist-patient conversations were targeted to obtain objective data on the interaction, understand the conversation framework, and uncover opportunities for improved communication.
View Article and Find Full Text PDFThe Quest for Understanding Diabetic Cardiomyopathy: Can We Preserve Function and Prevent Failure?
J Am Coll Cardiol
July 2024
Mount Sinai Fuster Heart Hospital, New York, New York, USA.
One-Month Versus Three-Month Dual-Antiplatelet Therapy in High Bleeding Risk Patients With Chronic Kidney Disease.
Am J Cardiol
August 2024
Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address:
Article Synopsis
- Shortening dual-antiplatelet therapy (DAPT) to 1 month after percutaneous coronary intervention (PCI) is effective and safe for high bleeding risk (HBR) patients, regardless of chronic kidney disease (CKD) status.
- A study analyzed data from 3 prospective studies involving 3,286 patients, of whom 43.6% had CKD, comparing outcomes between 1-month and 3-month DAPT.
- Results indicated that both durations had similar rates of death and myocardial infarction after 12 months, with a slight trend for fewer bleeding complications at 1 month compared to 3 months in both CKD and no-CKD groups.
Pulsed field ablation: A promise with future broad-based applicability or a pause needing further analysis-Is catheter ablation at a crossroads? A critical appraisal of the new challenger-pulsed field ablation.
Heart Rhythm
August 2024
Heart Rhythm Society, Washington, District of Columbia. Electronic address:
Clinical Trial Inclusion and Impact on Early Adoption of Medical Innovation in Diverse Populations.
JACC Heart Fail
July 2024
Norton Heart & Vascular Institute, Norton Healthcare, Louisville, Kentucky, USA.
Background: Inadequate inclusion in clinical trial enrollment may contribute to health inequities by evaluating interventions in cohorts that do not fully represent target populations.
Objectives: The aim of this study was to determine if characteristics of patients with heart failure (HF) enrolled in a pivotal trial are associated with who receives an intervention after approval.
Methods: Demographics from 2,017,107 Medicare patients hospitalized for HF were compared with those of the first 10,631 Medicare beneficiaries who received implantable pulmonary artery pressure sensors.
Author Correction: Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials.
Nat Commun
February 2024
Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, CA, USA.
1- Versus 3-Month DAPT in Older Patients at a High Bleeding Risk Undergoing PCI: Insights from the XIENCE Short DAPT Global Program.
Am J Cardiol
March 2024
Zena and Michael A. Wiener Cardiovascular Institute Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address:
Article Synopsis
- The analysis evaluated the impact of 1-month versus 3-month dual antiplatelet therapy (DAPT) in older patients after percutaneous coronary intervention (PCI), focusing on those with high bleeding risk.
- In a study of 3,364 patients, they found similar rates of all-cause death or myocardial infarction for both therapy durations, regardless of whether patients were ≥75 years or <75 years old.
- However, patients aged ≥75 experienced significantly less bleeding with the 1-month DAPT compared to the 3-month treatment, suggesting a clearer benefit in reducing bleeding risk without increasing heart-related complications.
Multicenter, Phase 2, Randomized Controlled Study of the Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of Rapid Ventricular Rate in Patients With Symptomatic Atrial Fibrillation (ReVeRA-201).
Circ Arrhythm Electrophysiol
December 2023
Department of Medicine, Montreal Heart Institute, Québec, Canada (G.G., M.-C.G., B.M., D.R.).
Background: Despite chronic therapies, atrial fibrillation (AF) leads to rapid ventricular rates (RVR) often requiring intravenous treatments. Etripamil is a fast-acting, calcium-channel blocker administered intranasally affecting the atrioventricular node within minutes.
Methods: Reduction of Ventricular Rate in Patients with Atrial Fibrillation evaluated the efficacy and safety of etripamil for the reduction of ventricular rate (VR) in patients presenting urgently with AF-RVR (VR ≥110 beats per minute [bpm]), was randomized, double-blind, placebo-controlled, and conducted in Canada and the Netherlands.
Association Between Polyvascular Disease and Transcatheter Aortic Valve Replacement Outcomes: Insights From the STS/ACC TVT Registry.
Circ Cardiovasc Interv
December 2023
Cardiology Division, Massachusetts General Hospital and Harvard Medical School, Boston (D.K.).
Article Synopsis
- Atherosclerotic cardiovascular disease is common in patients with severe aortic stenosis who are treated with transcatheter aortic valve replacement (TAVR), and the presence of polyvascular disease (PVD) significantly impacts patient outcomes.
- A study analyzed data from nearly 444,000 TAVR patients to examine the association of PVD with mortality and other complications after the procedure.
- Results showed that patients with PVD had higher 1-year all-cause mortality rates and more complications, with risks increasing as the number of affected vascular beds rose, particularly for those with three vascular beds involved.
Outcomes After Complex PCI With COMBO Stent Implantation: Insights from a Real-World Pooled Dataset.
Am J Cardiol
December 2023
The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address:
Article Synopsis
- The ADAPTABLE trial, a large study on aspirin dosing for preventing heart issues, showed no significant difference in efficacy between high- and low-dose aspirin in patients with cardiovascular disease.
- It explored whether using P2Y12 inhibitors like clopidogrel or prasugrel impacted aspirin's effectiveness or safety; however, results indicated no interaction between aspirin dose and P2Y12 inhibitor use.
- Participants taking P2Y12 inhibitors had a higher risk of major cardiovascular events but not an increased risk of bleeding, and switching doses was more common in the high-dose group without being influenced by P2Y12 inhibitor status.
1- or 3-Month DAPT in Patients With HBR With or Without Oral Anticoagulant Therapy After PCI.
JACC Cardiovasc Interv
October 2023
Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address:
Article Synopsis
- - The study examined the effects of 1-month vs. 3-month dual antiplatelet therapy (DAPT) in patients who had undergone percutaneous coronary intervention (PCI), particularly those on long-term oral anticoagulation (OAC) therapy.
- - Results showed that patients on OAC had similar rates of death or myocardial infarction (MI) whether they were on 1-month or 3-month DAPT, but those on 1-month therapy experienced lower rates of bleeding complications.
- - Overall, 1-month DAPT was found to be as effective as 3-month DAPT in preventing serious cardiovascular events while significantly reducing bleeding risks for patients, regardless of their OAC status.
Aims: Serial assessment of natriuretic peptides is widely utilized in heart failure clinics. Uncertainty exists regarding the value of multiple natriuretic peptide measurements and how they might be best interpreted.
Methods And Results: Six hundred thirty-two patients with heart failure with reduced ejection fraction (<40%) and complete biomarker data were enrolled to receive sacubitril/valsartan.
Anabolic androgenic steroids and cardiomyopathy: an update.
Front Cardiovasc Med
July 2023
Department of Cardiovascular, Duke University Medical Center and Duke Clinical Research Institute, Durham, NC, United States.
Anabolic androgenic steroids (AAS) include endogenously produced androgens like testosterone and their synthetic derivatives. Their influence on multiple metabolic pathways across organ systems results in an extensive side effect profile. From creating an atherogenic and prothrombotic milieu to direct myocardial injury, the effects of AAS on the heart may culminate with patients requiring thorough cardiac evaluation and multi-disciplinary medical management related to cardiomyopathy and heart failure (HF).
View Article and Find Full Text PDF